1. Immunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Populations
- Author
-
Andrea Favalli, Ennio Giulio Favalli, Andrea Gobbini, Elena Zagato, Mauro Bombaci, Gabriella Maioli, Elisa Pesce, Lorena Donnici, Paola Gruarin, Martina Biggioggero, Serena Curti, Lara Manganaro, Edoardo Marchisio, Valeria Bevilacqua, Martina Martinovic, Tanya Fabbris, Maria Lucia Sarnicola, Mariacristina Crosti, Laura Marongiu, Francesca Granucci, Samuele Notarbartolo, Alessandra Bandera, Andrea Gori, Raffaele De Francesco, Sergio Abrignani, Roberto Caporali, Renata Grifantini, Favalli, A, Favalli, E, Gobbini, A, Zagato, E, Bombaci, M, Maioli, G, Pesce, E, Donnici, L, Gruarin, P, Biggioggero, M, Curti, S, Manganaro, L, Marchisio, E, Bevilacqua, V, Martinovic, M, Fabbris, T, Sarnicola, M, Crosti, M, Marongiu, L, Granucci, F, Notarbartolo, S, Bandera, A, Gori, A, De Francesco, R, Abrignani, S, Caporali, R, and Grifantini, R
- Subjects
DMARD ,SARS-CoV-2 ,Antirheumatic Agents ,Rheumatic Diseases ,Immunology ,Humans ,COVID-19 ,Immunology and Allergy ,rheumatic musculoskeletal disease ,Immunosuppressive Agents ,immune response ,COVID-19 Drug Treatment ,inflammatory arthriti - Abstract
COVID-19 has proven to be particularly serious and life-threatening for patients presenting with pre-existing pathologies. Patients affected by rheumatic musculoskeletal disease (RMD) are likely to have impaired immune responses against SARS-CoV-2 infection due to their compromised immune system and the prolonged use of disease-modifying anti-rheumatic drugs (DMARDs), which include conventional synthetic (cs) DMARDs or biologic and targeted synthetic (b/ts) DMARDs. To provide an integrated analysis of the immune response following SARS-CoV-2 infection in RMD patients treated with different classes of DMARDs we carried out an immunological analysis of the antibody responses toward SARS-CoV-2 nucleocapsid and RBD proteins and an extensive immunophenotypic analysis of the major immune cell populations. We showed that RMD individuals under most DMARD treatments mount a sustained antibody response to the virus, with neutralizing activity. In addition, they displayed a sizable percentage of effector T and B lymphocytes. Among b-DMARDs, we found that anti-TNFα treatments are more favorable drugs to elicit humoral and cellular immune responses as compared to CTLA4-Ig and anti-IL6R inhibitors. This study provides a whole picture of the humoral and cellular immune responses in RMD patients by reassuring the use of DMARD treatments during COVID-19. The study points to TNF-α inhibitors as those DMARDs permitting elicitation of functional antibodies to SARS-CoV-2 and adaptive effector populations available to counteract possible re-infections.
- Published
- 2022
- Full Text
- View/download PDF